NCT06152744 Evaluation of Membrane Lung Function in High-altitude Regions
| NCT ID | NCT06152744 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Chao Yang Hospital |
| Condition | Extracorporeal Membrane Oxygenation |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-12-05 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2023-12-05 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Over the last 20 years, extracorporeal membrane oxygenation (ECMO) has been used to support adult patients with respiratory or cardiac failure who are unlikely to survive conventional treatment methods. ECMO circuit, pump, and oxygenator technology improvements permit safer perfusion for extended periods. The prolonged use of an ECMO circuit increases the risk of membrane lung (ML) dysfunction. The ML is responsible for taking in oxygen and removing carbon dioxide. The non-biologic surface of the ML triggers inflammatory and coagulation pathways, resulting in the formation of blood clots, breakdown of fibrin, and activation of white blood cells, which ultimately leads to ML dysfunction. Coagulation and fibrinolysis activation can cause systemic coagulopathy or hemolysis, and the deposition of blood clots can block blood flow. Moreover, the accumulation of moisture in the gas phase and the buildup of protein and cellular debris in the blood phase may contribute to shunt and dead-space physiology, respectively, impairing the exchange of gases. These three categories-hematologic abnormalities, mechanical obstruction, and inadequate gas exchange-account for most ML exchanges. Worsening oxygenation during ECMO should prompt quantification of oxygen transfer. ML exchange is indicated when the ML can no longer meet the patient's oxygen demand. The partial pressure of Post-ML arterial oxygen less than 200 mmHg is the most important consideration in this decision. In some high-altitude regions of China, ECMO treatment is also routinely conducted. The experiences above are derived from low-altitude areas, and whether they apply in high-altitude regions is still being determined. This study aimed to explore the significantly lower membrane lung oxygen uptake in high-altitude regions compared to low-altitude areas.
Eligibility Criteria
Inclusion Criteria: * Receiving ECMO support Exclusion Criteria: * Unable to obtain post-membrane blood gas * Pregnancy * Patients cannot receive anticoagulation * Refusal to participate in the trial
Contact & Investigator
Rui Wang, Dr.
STUDY DIRECTOR
Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
Frequently Asked Questions
Who can join the NCT06152744 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Extracorporeal Membrane Oxygenation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06152744 currently recruiting?
Yes, NCT06152744 is actively recruiting participants. Contact the research team at xuanben1985@163.com for enrollment information.
Where is the NCT06152744 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06152744 clinical trial?
NCT06152744 is sponsored by Beijing Chao Yang Hospital. The principal investigator is Rui Wang, Dr. at Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. The trial plans to enroll 40 participants.